← Leaderboards
Marco Ruella
University Of Pennsylvania
$5,145,541
Attributed
$7,261,774
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,840,183 · 4
FDA$3,421,591 · 1
By mechanism
R01$4,232,466 · 2
R37$2,073,174 · 1
R00$607,942 · 1
K99$348,192 · 1
Top collaborators
- Stefan Klaus Barta1 shared
- Vijay Bhoj1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Aimee S Payne$10,136,122
- John R Stanley$7,319,814
- Donald Siegel$2,588,217
- Nicola J Mason$7,580,948
- Megan H Noe$765,799
Others in their field
Other Emerging Leaders on “Cd19 Gene”
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,144,108
- Crystal Mackall · Children'S Hosp Of Philadelphia$12,826,300
- Michael C. Milone · Children'S Hosp Of Philadelphia$4,743,472
- Lili Wang · Dana-Farber Cancer Inst$3,456,689
- Weiqiang Chen · New York University$3,255,344
- Terry J. Fry · University Of Colorado Denver$3,169,598
Research focus
Cd19 GeneRefractoryT-LymphocyteMouse ModelClinical TrialsCellsRelapseT Cell TherapyIn VivoIn VitroAntigensInnovationResponseB-LymphocytesMalignant NeoplasmsLeukemia/LymphomaMissionCancer ImmunotherapyB-Cell LeukemiaCancer TherapyPathway InteractionsInvestigationB Lymphoid MalignancyImmunoregulation
Grant awards (11)
CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T cell non-Hodgkin lymphoma (NHL): a first-in-human phase I clinical trial$3,421,591
R01 · FY2025 · FD
Selective B Cell Depletion Using Engineered T Cells As A Curative Treatment For Acquired Thrombotic Thrombocytopenic Purpura$810,875
R01 · FY2025 · HL
MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER$527,525
R37 · FY2025 · CA · contact PI
MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER$501,149
R37 · FY2024 · CA · contact PI
MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER$516,975
R37 · FY2023 · CA · contact PI
MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER$527,525
R37 · FY2022 · CA · contact PI
Resistance To Targeted Immunotherapies:CART19 as a Paradigm$248,999
R00 · FY2020 · CA · contact PI
Resistance To Targeted Immunotherapies:CART19 as a Paradigm$109,944
R00 · FY2019 · CA · contact PI
Resistance To Targeted Immunotherapies:CART19 as a Paradigm$248,999
R00 · FY2018 · CA · contact PI
Resistance To Targeted Immunotherapies:CART19 as a Paradigm$174,096
K99 · FY2018 · CA · contact PI
Resistance To Targeted Immunotherapies:CART19 as a Paradigm$174,096
K99 · FY2017 · CA · contact PI